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Abstract
Aims-To investigate the expression pat-
tern of Epstein-Barr virus (EBV) latent
genes at the single cell level in post-
transplantation lymphoproliferative dis-
orders and acquired immunodefiency
syndrome (AIDS) related lymphomas, in
relation to cellular morphology.
Methods-Nine post-transplantation lym-
phoproliferative disorders and three
AIDS related lymphomas were subjected
to immunohistochemistry using mono-
clonal antibodies specific for EBV nuclear
antigen 1 (EBNA1) (2H4), EBNA2 (PE2
and the new rat anti-EBNA2 monoclonal
antibodies 1E6, R3, and 3E9), and LMP1
(CS1-4 and S12). Double staining was
performed combining R3 or 3E9 with S12.
Results-R3 and 3E9 anti-EBNA2 mono-
clonal antibodies were more sensitive than
PE2, enabling the detection of more
EBNA2 positive lymphoma cells. Both in
post-transplantation lymphoproliferative
disorders and AIDS related lymphomas,
different expression patterns were de-
tected at the single cell level. Smaller neo-
plastic cells were positive for EBNA2 but
negative for LMP1. Larger and more blas-
tic neoplastic cells, sometimes resembling
Reed-Sternberg cells, were LMP1 positive
but EBNA2 negative (EBV latency type
II). Morphologically intermediate neo-
plastic cells coexpressing EBNA2 and
LMP1 (EBV latency type III), were de-
tected using R3 and 3E9, and formed a
considerable part of the neoplastic popu-
lation in four of nine post-transplantation
lymphoproliferative disorders and two of
three AIDS related lymphomas. All sam-
ples contained a subpopulation of small
tumour cells positive exclusively for
Epstein-Barr early RNA and EBNA1. The
relation between cellular morphology and
EBV expression patterns in this study was
less pronounced in AIDS related lympho-
mas than in post-transplantation lympho-
proliferative disorders, because the AIDS
related lymphomas were less polymorphic
than the post-transplantation lymphopro-
liferative disorders.
Conclusions-In post-transplantation
lymphoproliferative disorders and AIDS
related lymphomas, EBV latency type III
can be detected by immunohistochemis-
try in a subpopulation of tumour cells
using sensitive monoclonal antibodies R3
and 3E9. Our data suggest that EBV
infected tumour cells in these lymphomas
undergo gradual changes in the expres-
sion of EBV latent genes, and that these
changes are associated with changes in
cellular morphology.
(J Clin Pathol 1997;50:91 1-918)
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Epstein-Barr virus (EBV) is the causative agent
of infectious mononucleosis.' In vitro, EBV can
transform B lymphocytes, resulting in lymphob-
lastoid cell lines (LCLs). Moreover, the virus
exhibits a strong association with endemic
Burkitt's lymphoma,2 nasopharyngeal carci-
noma, Hodgkin's disease,3 nasal T non-
Hodgkin's lymphoma,' and natural killer (NK)
cell lymphoma6 in immunocompetent patients.
EBV is also associated with lymphomas of
immunocompromised patients,7 such as ac-
quired immunodefiency syndrome (AIDS) re-
lated lymphomas and post-transplantation lym-
phoproliferative disorders. EBV is thought to
contribute to malignant transformation in all of
these these disorders.3 In LCLs and EBV
positive malignancies, the virus is present
latently and is transcriptionally active. To date,
12 gene products have been detected in
association with EBV latency. However, in EBV
positive lymphomas in immunocompetent pa-
tients, usually the EBV gene expression pattern
is restricted. A limited expression pattern
termed latency type I8 is detected in Burkitt's
lymphoma. This implies expression of the tran-
scription factor EBV nuclear antigen 1
(EBNA1), the small non-coding RNAs EBER1
and 2, and the BARFO transcripts.9 In EBV
positive Hodkin's disease and nasal T non-
Hodgkin's lymphomas in immunocompetent
patients, the Epstein-Barr early RNAs (EBERs),
EBNA1, and BARFO are expressed together
with the latent membrane proteins LMP 1,
LMP2a, and LMP2b'0 " (latency type II).8 In
LCLs, the expression pattern is extended to
EBNA2, EBNA3a, EBNA3b, EBNA3c, and
EBNA4 transcripts. 2 This extensive expres-
sion pattern is termed latency type II.8
In vivo, latency type III-like expression
patterns have been found in post-
transplantation lymphoproliferative disorders
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using non-morphological methods such as
western blotting'3 and reverse transcriptase
polymerase chain reaction (RT-PCR).'4 Using
immunohistochemical staining specific for
EBNA2 and LMP1 (monoclonal antibodies
PE2 and monoclonal antibody cocktail CS 1-4,
respectively), Rea et all'5 16 reported either
latency type I, II, or III in different post-
transplantation lymphoproliferative disorder
biopsies depending on whether the phenotype
was monomorphic or polymorphic. However,
the detection of latency type II instead of type
III in some polymorphic post-transplantation
lymphoproliferative disorders in the latter
study is attributed partly to the low sensitivity
of the PE2 anti-EBNA2 monoclonal antibody.
This low sensitivity may also have prevented
Oudejans et al from detecting latency type III at
the single cell level in post-transplantation
lymphoproliferative disorders using immuno-
histochemical double staining specific for
EBNA2 (monoclonal antibody PE2) and
LMP1 (monoclonal antibody S12),'7 resulting
in the conclusion that the latency type III pat-
tern in post-transplantation lymphoprolifera-
tive disorders (as found by western blotting)
was the result of at least three different
subpopulations of lymphoma cells.
EBV positive AIDS related lymphomas share
some common features with EBV positive
post-transplantation lymphoproliferative disor-
ders. Both lymphoma subtypes arise in patients
with an impaired immune response. Moreover,
the same EBV proteins have been detected in
both disorders."5 181 In addition, similar mor-
phological features have been reported in both
lymphoma types, for instance the presence of
Reed-Sternberg-like blasts.'8 19 It was demon-
strated that polymorphic AIDS related lym-
phomas harbour more LMP 1 positive
lymphoma cells than monomorphic AIDS
related lymphomas, and that LMP1 positive
AIDS related lymphoma cells are usually of the
Reed-Sternberg-like type 8 20 as in post-
transplantation lymphoproliferative disor-
ders.'7 Coexpression of LMP1 and other EBV
proteins at the single cell level has not been
studied before in AIDS related lymphomas.
There are several indications for the pres-
ence of latency type III at the single cell level in
both types of lymphoma. First, EBNA2 is
known to be a transactivator of other EBV
genes including LMP1.2 ' Therefore, it is likely
Table 1 Characteristics of clinical material
Cause ofimmune
Case suppression Biopsy site Histology
I Allogeneic BMT Lymph node Polymorphic, large cell B
2 Allogeneic BMT Lymph node Polymorphic, large cell B
3 Allogeneic BMT Lymph node Polymorphic, large cell B
4 Allogeneic BMT Lymph node Polymorphic, large cell B
5 Allogeneic BMT Lymph node Immunoblastic
6 Allogeneic BMT Lymph node Polymorphic, large cell B
7 Allogeneic BMT Lymph node Polymorphic centroblastic
8 Kidney transplantation Kidney Polymorphic centroblastic
9 Kidney transplantation Lymph node Immunoblastic
10 AIDS Lymph node Large cell B
11 AIDS CNS Polymorphic centroblastic
12 AIDS Lymph node Polymorphic
13 Not applicable Lymph node neck Not applicable
Post-transplantation lymphoproliferative disorder case 1 proved to be monoclonal, case 3
oligoclonal, and case 4 monocolonal as determined by Southern blotting analysis.
that at certain stages oflymphomagenesis these
gene products are present in lymphoma cells
simultaneously, especially in lymphomas of
immuncompromised patients where EBNA2
expressing-and thus immunogenic lymph-
oma cells are not eradicated because of the
impaired immune response. Second, Kerr et
a122 showed that, in vitro, EBV infected cells
can switch from a latency type I to latency type
III and, subsequently, back to latency type I or
II; hence transition from one EBV latency pat-
tern to another is possible. Also, such transi-
tions may be reflected by the different cellular
phenotypes observed within individual post-
transplantation lymphoproliferative disorder
biopsies.'5 16 23 24 However, proper diagnostic
tools are indispensable because some cells
might express low amounts of protein. Re-
cently, a new set of highly sensitive anti-
EBNA2 monoclonal antibodies was
developed.25 Using these antibodies in combi-
nation with an anti-LMP 1 monoclonal anti-
body we investigated expression ofEBNA2 and
LMP1, along with EBNA1, and EBER1 and 2
at the single cell level in relation to cellular
morphology in several lymphomas of immuno-
compromised patients with post-trans-
plantation lymphoproliferative disorders and
AIDS related lymphomas.
Methods
CELL LINES
The EBV positive cell lines JY, Raji, X507, JC5,
HH514.C 16 (infected with an EBNA2 deleted
EBV strain), and the EBV negative cell line
Ramos were cultured at 37°C in RPMI 1640
containing 10% fetal calf serum (FCS) in a
humidified atmosphere containing 5% Co2.
Cell suspensions were embedded in cellulose
(cytoblock kit; Shandon, Pittsburgh, Pennsyl-
vania, USA), fixed in buffered formalin, and
embedded in paraffin. Sections of 4 gm were
cut for immunohistochemistry.
CLINICAL MATERIAL
Four cases of post-transplantation lymphopro-
liferative disorder were obtained from the
department of pathology of the Academical
Hospital, Leiden. Material from five post-
transplantation lymphoproliferative disorders,
three AIDS related lymphomas, and one infec-
tious mononucleosis case was obtained from
the Academical Hospital of Utrecht. Charac-
teristics of these samples are summarised in
table 1. The site of origin of these tumours was
difficult to determine as most of them were
generalised at the time of diagnosis. Instead,
the site ofbiopsy is mentioned when known. To
verify EBV association, EBER RNA in situ
hybridisation was performed on 4 ,um paraffin
sections as described previously.26 As a positive
control for EBER RNA in situ hybridisation,
an EBV positive case of Hodgkin's disease was
used. Hybridisation of all samples with the
EBER sense probe served as a negative control;
moreover, the non-neoplastic infiltrate in the
EBV positive Hodgkin's disease case was
always negative using EBER RNA in situ
hybridisation. Immunohistochemistry was also
performed on 4 gm sections.
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mer, Munich, Germany). R3 recognises
epitopes specific for EBV type 1, 3E9 recog-
nises EBV type 2 encoded EBNA2, and 1E6
recognises both.25 As a reference for sensitivity
the anti-EBNA2 monoclonal antibody PE2
(Dako, Glostrup, Denmark) was used. As a
reference for the specificity of these mono-
clonal antibodies for the two EBV types we
compared immunohistochemistry with DNA
PCR. For detection of LMP1, both mouse
LMP1 anti-LMP1 monoclonal antibody S12 (Orga-
non Teknika, Boxtel, Netherlands) and the
mixture of four anti-LMP1 antibodies CS1-4
(Dako) were used. EBNA1 protein was de-
tected using the 2B4 monoclonal antibody28
(kindly provided by Dr E Kremmer, Munich,
Germany).
-34
-27
Figure 1 Western blotting analysis to compare sensitivities of the anti-EBNA2
monoclonal antibodies R3 (A) and PE2 (B), and the anti-LMP1 monoclonal antibodies
S12 (C) and CS1-4 (D). R3 and PE2 detect the 88 kDa EBNA2A protein with
comparable efficiency in western blotting. The 66 kDa LMP1 protein is detected more
efficiently by S12 than by CS1-4.
Of the EBV positive lymphomas, eight post-
transplantation lymphoproliferative disorders
were shown to harbour EBV type 1 using DNA
PCR with EBNA2 specific primers as de-
scribed previously27 (one sample was not tested
owing to lack of material). Two AIDS related
lymphomas contained EBV type 1, and one
AIDS related lymphoma contained EBV type
2. As shown by DNA PCR, the EBV positive
cell lines harboured EBV type 1 with the
exception ofJC5, which contained EBV type 2.
Furthermore, all lymphomas and EBV posi-
tive cell lines were shown to express EBNA1,
EBNA2, and LMP1 at the mRNA level using
RT-PCR as described previously,"4 with the
exception of the HH514C16 cell line, which
did not express EBNA2 owing to a genomic
deletion.
MONOCLONAL ANTIBODIES
To enable efficient detection of low concentra-
tions ofEBNA2 protein, we used several highly
sensitive anti-EBNA2 rat monoclonal antibod-
ies, which have been developed recently (R3,
3E9, and 1E6, kindly provided by Dr E Krem-
Table 2 Immunohistochemical analysis ofEBNA2 expression in cell lines comparing
different anti-EBNA2 monoclonal antibodies
EBNA2 % EBNA21
EBNA2A EBNA2B LMP1 double
Cell line EBV type* MoAb PE2 MoAb 1E6 MoAb R3 Mo Ab3E9 staining
Raii 1 90 95 >95 0 90
JY 1 90 95 >95 0 90
X50.7 1 90 95 >95 0 90
JC5 2 90 95 0 >95 90
HH514C16 -t0 0 0 0 0
Ramos 0 0 0 0 0
Values are percentage of cultured cells staining positively.
In all cell lines, a proportion of 90% stained positive for EBNA1 and LMP1 using immunohisto-
chemistry, with the exception of the EBV negative cell line Ramos (negative for both EBNA1 and
LMP1) and the HH514C16 cell line (<5% LMPI positive).
*As determined by DNA-PCR using EBNA2 specific primers.27
tIn the HH5 1 4C 16 cell line, no EBV typing with EBNA2 specific PCR was possible because of a
genomic deletion in the EBNA2 region.
WESTERN BLOT ANALYSIS OF EBV PROTEINS
Western blots were prepared from SF9 insect
cells, transfected with EBNA2A or LMP1
recombinant baculovirus (kindly provided by
Dr P Meij, University Hospital Vrije Univer-
siteit, Amsterdam, Netherlands). Each lane
contained the crude lysate of 10' SF9 cells.
Blots were incubated for one hour in blocking
buffer (5% FCS, 5% milk powder in phosphate
buffered saline (PBS)) followed by one hour
incubation with primary antibodies diluted
1/100 in blocking buffer. After washing three
times for five minutes in PBS/0.05% Tween 20,
blots were incubated for one hour with second-
ary antibodies-rabbit antimouse horseradish
peroxidase (HRP) (Dako) and rabbit antirat
HRP (Dako), both diluted 1/1000 in blocking
buffer. The peroxidase was visualised for one
hour using 0.05% naphtol/0.0 1% H202 in PBS.
IMMUNOHISTOCHEMISTRY OF EBV PROTEINS
Single staining
All immunohistochemistry was performed on
formalin fixed, paraffin embedded material.
Sections were deparaffinised with xylene and
rehydrated; endogenous peroxidase was inacti-
vated by incubation with 0.3% H202 in metha-
nol for 30 minutes. Antigens were retrieved by
boiling the slides in 0.1 M citrate buffer pH 6.0
for 10 minutes. Slides were incubated with the
primary antibody and subsequently with bioti-
nylated secondary antibodies. A biotinylated
rabbit antimouse antiserum (1/500; Dako) was
used for detection of those primary antibodies
raised in mice, whereas a biotinylated goat
antirat antiserum (1/500; Jackson Immunore-
search, West Grove, Pennsylvania, USA) was
used to detect primary antibodies raised in rats.
Detection of antibody complexes was per-
formed using an avidin-biotin-HRP complex
(sABC; Dako). The peroxidase was visualised
by incubation for three minutes in 0.4 mg/ml
diaminobenzidine (DAB), 0.002% H202 in
50 mM Tris HC1, pH 7.6 (brown staining). To
provide a negative control for the immunos-
taining, primary antibodies were substituted
with PBS.
Double staining
Slides were pretreated as for single staining.
Slides were incubated with R3 or 3E9 anti-
EBNA2 monoclonal antibodies followed by
A B
C D
EBNA2 -
kD
- 108
- 80
- 51
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Table 3 Immunohistochemical analysis ofEBNAI, EBNA2 (comparing different monoclonal antibodies), and LMP1
expression in post-transplantation lymphoproliferative disorders, AIDS related lymphomas, and infectious mononucleosis
EBNA2
EBNA2A EBNA2B EBNA1 LMPI % EBNA21 LMPI
Sample EBVtype* MoAb PE2 MoAb 1E6 MoAb R3 MoAb 3E9 MoAb 2B4 MoAb S12 double staining
Post-transplantation lymphoproliferative disorders
1 ND 25-50 50-75 >90 0 >90 0 ND
2 1 50 50-75 75-90 0 50 <1 ND
3 1 <5 5-10 10 0 5-10 10-20 5
4 1 50-75 90 >90 0 50 0 ND
5 1 50-75 50-75 50-75 0 50-75 50 25
6 1 25-50 50-75 75 0 50-75 10-25 5
7 1 <5 <5 <5 0 <5 <5 ND
8 1 25-50 50-75 75-90 0 50-75 0 ND
9 1 <5 25-50 25-50 0 10-20 50 30
AIDS related lymphomas
10 2 50-75 75 0 75 50-75 5-10 5
11 1 5-10 5-10 25 0 5-10 10-25 5
12 1 75 75 75 0 50-75 0 ND
Infectious mononucleosis
13 ND 10-25 50 50 0 50 10-25 5
Values are percentage of total neoplastic population staining positively.
*As determined by DNA PCR using EBNA2 specific primers.27
ND, not determined.
biotinylated goat antirat and sABC, and these
complexes were visualised by incubation for 10
minutes in 0.2 mg/ml DAB, 0.002% H),O and
0.12% NiSO4/(NH4),S04 in 50 mM Tris HCI,
pH 7.6 (black staining). Remaining peroxidase
was inactivated as described above and slides
were fixed for 10 minutes using 4% parafor-
maldehyde in PBS. Slides were then incubated
with S12 anti-LMP1 monoclonal antibody fol-
lowed by biotinylated rabbit antimouse and
sABC. This antibody complex was visualised
by incubation for three minutes in 0.4 mglml
DAB, 0.002% H202 in 50 mM Tris HCI,
pH 7.6 (brown staining).
Results
EVALUATION OF ANTI-EBNA2 MONOCLONAL
ANTIBODIES
The anti-EBNA2 antibodies R3 and PE2 were
compared for their sensitivities in western blot
analysis (fig 1) and were found to be almost
equally sensitive in the recognition of linear
epitopes. However, when PE2 was compared
with the new rat monoclonal antibodies in
immunohistochemistry, clear differences in
sensitivity were observed, which are summa-
rised in tables 1 and 2. All three new
monoclonals showed both a higher number of
positive cells and higher staining intensities in
cell lines, post-transplantation lymphoprolif-
erative disorders, AIDS related lymphomas,
and infectious mononucleosis (tables 2 and 3;
figs 2 and 3). Using PE2 in immunohistochem-
istry on clinical material, EBNA2 was detected
mainly in smaller tumour cells (fig 2A),
whereas 1E6 and R3 also stained some larger,
more blastic tumour cells (figs 2B and 4A).
The low sensitivity of PE2 may be because the
epitope recognised by this antibody is con-
cealed by formalin fixation of the tissue.
Specificities of the monoclonal antibodies
for the EBV types 1 and 2 were determined in
those cases where the EBV type had been
determined previously using DNA PCR. Im-
munohistochemistry results correlated well
with DNA PCR results: R3 recognised only
EBV type 1 encoded EBNA2, whereas 3E9
recognised type 2 encoded EBNA2 exclusively,
and 1E6 and PE2 recognised both (tables 2
and 3). Based on these results, R3 and 3E9
appeared to be most suitable for detection of
EBNA2 protein.
EVALUATION OF ANTI-LMP1 MONOCLONAL
ANTIBODIES
Sensitivities of the monoclonal anti-LMP1
antibody S12 and the monoclonal antibody
B
UP
Figure 2 Immunohistochemical analysis ofEBNA2 expression in post-transplantation lymphoproliferative disorder case 2, comparing the monoclonal
antibodies PE2 and R3. (A) With PE2, -50% of the neoplastic population is EBNA2 positive. (B) With R3, -90% of the neoplastic population stains
positively for EBNA2. The staining intensity obtained with 1E6 and R3 is stronger than that obtained with PE2.
A
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for the immunohistochemical detection of
LMP1 in cell lines and clinical material in the
present study.
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4 *. - EXPRESSION OF EBV LATENT GENES IN CELL LINES
AND CLINICAL MATERIAL
As previously shown by RT-PCR, all lympho-
mas and cell lines except HH5 14C 16 (contain-
ing an EBV strain with an EBNA2 deletion)
;:=b and Ramos (an EBV negative Burkitt's
^ lymphoma cell line), expressed EBNA2 and
LMP1 at the mRNA level. This is indicative of
an EBV latency type III expression pattern.
However, in immunohistochemical assays
using the R3 and 3E9 anti-EBNA2 mono-
clonals and the S12 anti-LMP1 monoclonal
antibody, differences between the in vitro and
in vivo situations at the single cell level were
observed.
Cell lines
EBNA1 was detected in 90% of cultured EBV
positive cells. LMP1 was also detected in 90%
of cultured cells, except in the cell line
HH514C16 in which LMP1 was expressed in
less than 5% of cells. Using the sensitive
anti-EBNA2 monoclonal R3 (or 3E9 for cell
line JC5), EBNA2 was detected in > 95% of
HiW¢ cultured cells. EBNA2 was not detected in the
cell lines HH514C 16 (EBNA2 deficient) and
Ramos (EBV negative) (table 2).
Infectious mononucleosis
The infectious mononucleosis case showed
EBNA2 positivity in 50% of the EBV positive
cells. Of the EBV positive cells, 10-25% were
LMP1 positive; these were mainly large Reed-
Sternberg-like blasts, which are often seen in
C infectious mononucleosis; EBNA1 protein was
detected in 50% of the EBV positive cells, both
in large blasts and in smaller cells.
Figure 3 (A) EBER RNA in situ hybridisation analysis ofpost-transplantation
lymphoproliferative disorder case 9. (B) EBNA1 and (C) EBNA2 immunohistochemical
analysis of the same case. Both EBNA 1 and EBNA2 are expressed in large and small
neoplastic cells.
mixture CS1-4 were compared using western
blot analysis (fig 1). Using the S 12 monoclonal,
stronger signals were obtained than with
CS 1-4. Previously, it was demonstrated by Jiwa
et al that in immunohistochemical assays, S 12
gives stronger signals and stains more cells
positive than CS1-429; therefore, S12 was used
Post-transplantation lymphoproliferative disorders
In this disorder, numbers of EBNA2 positive
cells varied from 5-90% of the neoplastic
population using the R3 monoclonal.
EBER1/2, EBNA1, and EBNA2 staining of
successive slides revealed the presence, of a
small population positive exclusively for
EBER1/2 and EBNA1. EBNA1 was detected
in both large and small neoplastic cells (fig 3).
None ofthe post-transplantation lymphoprolif-
erative disorders stained positive with the 3E9
monoclonal antibody, which is specific for EBV
type 2 encoded EBNA2. This was in agree-
ment with DNA PCR results, which had
revealed the presence of EBV type 1 but not
type 2 in all of the post-transplantation
lymphoproliferative disorder biopsies.
Using the S12 anti-LMP1 monoclonal anti-
body, LMP1 expression could be detected only
in the cytoplasm and membranes of large blas-
tic, sometimes Reed-Sternberg-like tumour
cells (fig 4B). In smaller tumour cells, LMP1
was not detected. Six out of nine post-
transplantation lymphoproliferative disorders,
and the infectious mononucleosis case stained
positive for LMP 1 (table 3).
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A B
Figure 4 Immunohistochemical analysis ofLMP1 and EBNA2 expression in post-transplantation lymphoproliferative disorder case 6. (A) EBNA2, as
detected by the R3 monoclonal antibody, is expressed in smaller neoplastic cells and to a lesser extent in some of the larger, more anaplastic cells. (B) LMPI
protein, as detected by the S12 monoclonal antibody, is detected mainly in the membranes of large neoplastic cells.
AIDS related lymphomas
In two of the three AIDS related lymp
5-75% of the lymphoma cells were I
positive using the R3 antibody (samples
12, table 3). One AIDS related lyr
sample showed staining with PE2 and I
not with R3 (sample 10, table 3). For th
sample DNA PCR had shown the pres
EBV type 2 and, indeed, using ti
antibody specific for EBV type 2 e
EBNA2, staining was observed in 750M
tumour cells. As in the post-transpla
lymphoproliferative disorder, EE
EBNA1, and EBNA2 staining of cons
slides showed a small population positi
for EBER1/2 and EBNA1.
LMP1 expression was detected
cytoplasm and membranes of tumour
two of the three AIDS related lymj
using the S12 anti-LMP1 monoclon
body (table 3). LMP1 positive tumour
AIDS related lymphomas were larger ar
blastic than LMP1 negative tumour cc
clear Reed-Sternberg-like features, as ol
in abundance in post-transplantation 1:
A.
44.~ ~~.
* V:.
Figure 5 Double stainingfor EBNA2 (black) and LMPJ (brown) in
post-transplantation lymphoproliferative disorder case 6. This staining shows a con
spectrum of smaller tumour cells staining strongly for EBNA2, but staining relativi
weakly for LAMP, via intermediate phenotypes to larger, more anaplastic tumour
resembling (mononuclear variants of) Reed-Sternberg cells, staining positively forbut negatively for EBNA2.
proliferative disorders, were rare in AIDS
related lymphomas.
COEXPRESSION OF EBNA2 AND LMP1
Iphoma Double staining for EBNA2 and LMP1 was
1.E6 but performed using anti-EBNA2 monoclonal
s latter antibodies R3 and 3E9, and anti-LMP1
ence of antibody S12. Double staining was performed
he 3E9 on cell lines, and on those clinical samples in
ncoded which at least 5% of the EBV positive cells
'o of the stained positively for LMP1 in single staining
intation with S12; that is, in two cases of AIDS related
3ER1/2, lymphoma (cases 10 and 11, table 3), the
secutive infectious mononucleosis case (case 13, table
ive only 3), and four cases of post-transplantation lym-
phoproliferative disorders (cases 3, 5, 6, and 9,
in the table 3).
cells in In the JY, Raji, and X50.7 cell lines, double
phomas staining for EBNA2 and LMP1 was observed
al anti- in - 90% of cells using R3 and S12. Cell line
cells in JC5 (EBV type 2) showed 90% double staining
idmore using 3E9 and S12. Cell line HH514C16
ells, but remained EBNA2 negative but stained positive
bserved for LMP1 in less than 5% of the cells, whereas
ympho- the Ramos cell line remained negative for both
EBNA2 and LMP1. In the post-
transplantation lymphoproliferative disorders,
a continuous spectrum of cells with different
levels ofEBNA2 and LMP1 expression in cor-
relation to distinct morphological features was
detected. Four main tumour cell phenotypes
were observed in post-transplantation lympho-
proliferative disorders (figs 3 and 5):
(1) neoplastic cells negative for both EBNA2
and LMP1 but positive for EBER1 and
EBNA1, thus showing an EBV latency type I
expression pattern
(2) neoplastic cells staining strongly for
EBNA2 but staining weakly or not at all for
LMP1
(3) relatively large and blastic cells, even
resembling (mononuclear variants of) Reed-
Sternberg cells, showing expression of LMP1
but staining only weakly or not at all for
EBNA2 (EBV latency type II expression
pattern)
tinuous (4) neoplastic cells of intermediate size, ex-
elyl pressing varying amounts of both EBNA2 and
cells even LMP1, indicative of an EBV latency type IIILMPe,
expression pattern.
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Figure 6 Schematic representation of relative EBNA1, EBNA2, and LMPl ex
levels in post-transplantation lymphoproliferative disorders andAIDS related lyn
relation to cell morphology. Relatively small tumour cells express high amounts of
but no LMP1. It is tempting to assume that EBNA2 has upregulated the express
LMPI in the subsequent, more blastic phenotype. In the large blasts, which resem
mononuclear variants of Reed-Sternberg cells, high amounts ofLMPI are presen
EBNA2 is no longer expressed. EBNA I is expressed in all phenotypes.
In the AIDS related lymphomas sim
expression patterns were observed,
the LMP1 positive, EBNA2 negative c
not as large and blastic as in tl
transplantation lymphoproliferative
Moreover, these four expression patte
also detected in the infectious monoi
biopsy. Although the proportions of
different phenotypes varied in the
clinical samples, the small EBNA2
LMP1 negative cells, and the cells e)
both EBNA2 and LMP1 (latency 1
were most often observed in the three c
studied.
Discussion
In lymphomas of immunocomprom
tients, cells expressing immunogenic
such as EBNA2 during latency type III
eradicated owing to the lack of a host
response. Therefore, it is likely that all
EBV expression patterns can be det
these lymphomas. Indeed, in the prese
using the most sensitive monoclonal ai
available to date (R3 and 3E9 for EBN
for LMP1), all possible combinai
EBNA2 and LMP1 expression i:
latency type III, were observed in co
with certain morphological features
small tumour cells, either EBNA1+/E
LMP1- (latency type I) or E
EBNA2+/LMP1- (unknown pattern)
intermediate size staining positive i
EBNA2 and LMP1 (latency type III
more blastic, and in post-transplantat
phoproliferative disorders, even
Sternberg-like cells expressing high an
LMP1 but no or little EBNA2 (late.
II-like). The expression of LMP1 i:
more blastic cells in post-transplantat
phoproliferative disorders and AIDS
lymphomas is in agreement with
studies.'5 16 18 23
LMP 1 positive, EBNA2 negativ
transplantation lymphoproliferative
and AIDS related lymphomas ha,
observed in previous studies,'6 18 per]
cause the anti-EBNA2 monoclonal ar
used then were not sensitive enough.16
natively, EBNA2 transcriptional activation may
E. not always be the cause ofLMP1 expression."
In the present study, using highly sensitive
anti-EBNA2 and LMP1 monoclonal antibod-
ies, we show that latency type III does exist at
the single cell level in lymphomas of immuno-
compromised patients, a finding which has not
been reported previously. These results are
only found using the highly sensitive R3 and
++ 3E9 antibodies, which indicates that in cells
showing a latency type III pattern, EBNA2 is
expressed at a very low concentration. In fact,
+ latency type III cells seem to represent an
rpression intermediate between the EBNA2+/LMP1-
,phomas in and the EBNA2-/LMP1+ cells, both when
EBNA2 EBV expression and morphological features
ion of are considered. These results suggest that inble
It, whereas lymphomas of immunocompromised patients,
EBV infected cells are subject to a process in
which the latent EBV gene expression alters
lar EBV gradually, along with changes in morphological
although features.
Sells were Also, the heterogeneous EBV expression in
he post- the lymphomas of immunocompromised pa-disorder. tients revealed an interesting EBV expression
rns were pattern which could not be categorised as one
nucleosis of the "classic" latency types: relatively small
the four tumour cells that express EBNA2 but nodifferent LMP1. This is in agreement with a previous
positive, study in which, using the less sensitive PE2tpressing monoclonal antibody, a similar phenotype was
type III) observed in post-transplantation lymphoprolif-disorders erative disorders.'7 Based upon the expression
of the BZLF1 lytical activator in a proportion
of these smaller tumour cells, it was hypoth-
esised that these cells are tending towards a
lytical EBV infection. Alternatively, this pheno-
ised pa- type could reflect an intermediate between
proteins, latency types I and III, which is a subject for
I, are not future investigation.
immune Based on the combination of the transacti-
possible vating properties of EBNA2," the switches of
tected in EBV infected cells from one latency type to
-nt study another as observed in vitro,22 and the changes
nitibodies in morphological features observed in the
1A2, S12 present study, it is tempting to speculate that
tions of lymphoma cells in immunocompromised pa-
ncluding tients can switch from one phenotype-the
orrelation smaller, EBNA2+/LMP1- tumour cells-via
of cells: an intermediate phenotype with an EBV
BNA2-/ latency III expression pattern to the Reed-
BNA1+/ Sternberg-like phenotype expressing EBV la-
); cells of tency type II. A schematic representation of
for both this hypothesis is given in fig 6. Alternatively,
:); larger, different EBV expression patterns could reflect
:ion lym- different phases in the cell cycle.
Reed- In conclusion, this study has shown that
ounts of EBV latency type III at the single cell level does
ncy type exist in a subpopulation of cells in post-
n larger, transplantation lymphoproliferative disorders
ion lym- and AIDS related lymphomas when using the
5 related sensitive EBNA2 specific monoclonal antibod-
previous ies R3 and 3E9. Therefore, these antibodies are
highly recommended for the detection of
{e post- EBNA2 expression at the protein level. More-
disorders over, latency type III may represent a transi-
ve been tional stage between other EBV latency types in
haps be- lymphomas of immunocompromised patients.
ntibodies This is indicated by the fact that the major1
' Alter- classic latency types I, II, and III, which
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correlate to clearly distinct morphological fea-
tures, appear to be a part of a continuum of
EBV latency patterns.
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